ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 044,15
-1,90%
Dow Jones
43 191,24
0,00%
DAX
22 490,15
-2,81%
Brent Oil
70,525
-1,23%
Bitcoin
82 750,80
-3,88%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Inhibikase Therapeutics Inc (IKT) Cours

Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc (IKT)

NASDAQ
2,27
-0,03
(-1,30%)
Fermé 04 Mars 10:00PM
Retardé de 15 minutes
2,27
0,00
( 0,00% )
Avant marché: 3:04PM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,27
Prix Achat
2,23
Prix Vente
2,31
Volume échangé
31
0,00 Fourchette du Jour 0,00
1,12 Plage de 52 semaines 4,20
Cap du marché
152,527M
Clôture Veille
2,27
Ouverture
-
Dernière Transaction
21
@
2.31
Dernière heure de transaction
14:52:35
Volume financier
-
VWAP
-
Volume moyen (3 m)
277 016
Actions en circulation
67 192 570
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-8,02
Bénéfice par action (BPA)
-0,28
Chiffre d'affairess
261k
Bénéfice net
-19,03M

À propos de Inhibikase Therapeutics Inc

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to trea... Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.inhibikase.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Inhibikase Therapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker IKT. Le dernier cours de clôture d'Inhibikase Therapeutics était de US$2,27. Au cours de la dernière année, les actions de Inhibikase Therapeutics ont été négociées dans une fourchette de prix de US$ 1,12 à US$ 4,20.

Inhibikase Therapeutics compte actuellement 67 192 570 actions en circulation. La capitalisation boursière d'Inhibikase Therapeutics est de US$152,53 million. Inhibikase Therapeutics a un ratio cours/bénéfice (ratio PE) de -8.02.

IKT Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
25 Février 2025
IKT (-1,30%)

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
25 Février 2025
IKT (-1,30%)

Form 8-K - Current report
Edgar (US Regulatory)
24 Février 2025
IKT (-1,30%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 Février 2025
IKT (-1,30%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 Février 2025
IKT (-1,30%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 Février 2025
IKT (-1,30%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
20 Février 2025
IKT (-1,30%)

Form 8-K - Current report
Edgar (US Regulatory)
18 Février 2025
IKT (-1,30%)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
15 Février 2025
IKT (-1,30%)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.18-7.346938775512.452.912.1751688782.29812336CS
40.115.092592592592.163.322.071878882.53303453CS
12-0.96-29.72136222913.234.21.92770162.97200886CS
260.8964.49275362321.384.21.123973632.11338409CS
520.14.608294930882.174.21.122161292.07603998CS
156-4.03-63.96825396836.39.120.791984883.19243157CS
260-61.75-96.454233052264.0270.80.792366369.39292655CS

IKT - Frequently Asked Questions (FAQ)

What is the current Inhibikase Therapeutics share price?
The current share price of Inhibikase Therapeutics is US$ 2,27
How many Inhibikase Therapeutics shares are in issue?
Inhibikase Therapeutics has 67 192 570 shares in issue
What is the market cap of Inhibikase Therapeutics?
The market capitalisation of Inhibikase Therapeutics is USD 152,53M
What is the 1 year trading range for Inhibikase Therapeutics share price?
Inhibikase Therapeutics has traded in the range of US$ 1,12 to US$ 4,20 during the past year
What is the PE ratio of Inhibikase Therapeutics?
The price to earnings ratio of Inhibikase Therapeutics is -8,02
What is the cash to sales ratio of Inhibikase Therapeutics?
The cash to sales ratio of Inhibikase Therapeutics is 582,05
What is the reporting currency for Inhibikase Therapeutics?
Inhibikase Therapeutics reports financial results in USD
What is the latest annual turnover for Inhibikase Therapeutics?
The latest annual turnover of Inhibikase Therapeutics is USD 261k
What is the latest annual profit for Inhibikase Therapeutics?
The latest annual profit of Inhibikase Therapeutics is USD -19,03M
What is the registered address of Inhibikase Therapeutics?
The registered address for Inhibikase Therapeutics is 1313 N MARKET ST STE 5100, SUITE 101, WILMINGTON, DELAWARE, 19801
What is the Inhibikase Therapeutics website address?
The website address for Inhibikase Therapeutics is www.inhibikase.com
Which industry sector does Inhibikase Therapeutics operate in?
Inhibikase Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MASS908 Devices Inc
US$ 3,40
(71,72%)
11,72M
UOKAMDJM Ltd
US$ 0,226
(50,67%)
60,64M
IKTInhibikase Therapeutics Inc
US$ 2,91
(28,19%)
31
SWAGStran and Company Inc
US$ 1,30
(27,45%)
22
JFINJiayin Group Inc
US$ 8,8801
(25,60%)
97,85k
SPGCSacks Parente Golf Inc
US$ 0,1202
(-36,74%)
25,48M
EVCMEverCommerce Inc
US$ 6,20
(-36,28%)
7
OPCHOption Care Health Inc
US$ 22,01
(-35,19%)
70
NVNINVNI Group Ltd
US$ 0,2475
(-33,77%)
10,3M
INKTMiNK Therapeutics Inc
US$ 6,00
(-31,76%)
172
UOKAMDJM Ltd
US$ 0,23
(53,33%)
60,7M
BTOGBit Origin Ltd
US$ 0,3407
(6,70%)
53,63M
SUNESUNation Energy Inc
US$ 0,1979
(-17,54%)
53,34M
CYCUCycurion Inc
US$ 0,7333
(21,99%)
32,65M
PTIXProtagenic Therapeutics Inc
US$ 0,329801
(19,36%)
28,7M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
IKT
Inhibikase Therapeutics
BIT
UB3YRQ
Unicredit Bank
BIT
UI878A
Unicredit Bank
BIT
P1R2Z5
BNP Paribas Issuance
BIT
UC65MR
Unicredit Bank
BIT
UC0W37
Unicredit Bank
BIT
GEQ
Gequity
BIT
UC5LUZ
Unicredit Bank
BIT
UC59W5
Unicredit Bank
BIT
I06735
Intesa Sanpaolo
BIT
UB7HNW
Unicredit Bank
BIT
UB82HL
Unicredit Bank
BIT
UC610K
Unicredit Bank
BIT
UC8AMY
Unicredit Bank
NASDAQ
AACG
ATA Creativity Global
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces